SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Liwing Johan)
 

Sökning: WFRF:(Liwing Johan) > Real-world study of...

  • Schain, FridaJanssen Global Serv, Stockholm, Sweden.;Karolinska Inst, Div Hematol, Dept Med, Solna, Sweden.;Schain Res, Bromma, Sweden. (författare)

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2020-12-04
  • Springer Nature,2021
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-438827
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-438827URI
  • https://doi.org/10.1007/s10198-020-01249-xDOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:145371733URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as 'non-cGVHD' if they received no immunosuppressive treatment, 'mild cGVHD' if they received only systemic corticosteroid treatment or immunosuppressive treatment, or 'moderate-severe cGVHD' if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate-severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate-severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Batyrbekova, NurgulKarolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Scandinavian Dev Serv, Stockholm, Sweden. (författare)
  • Liwing, JohanJanssen Global Serv, Stockholm, Sweden.;Karolinska Inst, Dept Med, Div Hematol, Huddinge, Sweden. (författare)
  • Baculea, SimonaJanssen Global Serv, High Wycombe, Bucks, England. (författare)
  • Webb, ThomasJanssen Global Serv, High Wycombe, Bucks, England. (författare)
  • Remberger, MatsUppsala universitet,Hematologi,Uppsala Univ Hosp, KFUE, Uppsala, Sweden(Swepub:uu)matre804 (författare)
  • Mattsson, JonasKarolinska Institutet (författare)
  • Janssen Global Serv, Stockholm, Sweden.;Karolinska Inst, Div Hematol, Dept Med, Solna, Sweden.;Schain Res, Bromma, Sweden.Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Scandinavian Dev Serv, Stockholm, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Journal of Health Economics: Springer Nature22:1, s. 169-1801618-75981618-7601

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy